[Skip to Content]
[Skip to Content Landing]
July 4, 2001

Placing PRINCE in Perspective

Author Affiliations

Author Affiliation: Cardiology Section, University of North Carolina, Chapel Hill.

JAMA. 2001;286(1):91-93. doi:10.1001/jama.286.1.91

In this issue of THE JOURNAL, Albert and colleagues1 present the main results of the Pravastatin Inflammation/CRP Evaluation (PRINCE) study, a randomized clinical trial and prospective cohort study evaluating the effects of pravastatin on levels of high sensitivity C-reactive protein (CRP). The investigators randomly assigned men and women with elevated low-density lipoprotein cholesterol (LDL-C) levels and no apparent coronary disease to receive placebo or pravastatin to assess the change in CRP levels at 24 weeks independently of the change in lipids. An additional cohort of patients with established coronary disease received open label pravastatin to determine the effect on CRP among these patients as well.

First Page Preview View Large
First page PDF preview
First page PDF preview